Multi-center study for efficacy of TAZ/PIPC on catheter-associated urinary tract infection (CAUTI)

Multi-center study for efficacy of TAZ/PIPC on catheter-associated urinary tract infection (CAUTI) - Efficacy of TAZ/PIPC on catheter-associated urinary tract infection (CAUTI)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000032200

Enrollment

100

Registered

2018-04-11

Start date

2018-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Catheter-associated urinary tract infection

Interventions

TAZ/PIPC group 13.5g/day for 1 week

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Those patients with CAUTI who are older than 20 years old.

Exclusion criteria

Exclusion criteria: Those patients with allergy for TAZ/PIPC. Those patients with the previous UTI whiose causative bacteria showed TAZ/PIPC-resistance.

Design outcomes

Primary

Measure	Time frame
TAZ/PIPC 13.5g/day treatment on CAUTI will be done for 1 week and 1st outcome evaluation will be don, then antibiotics will be switched to oral one by de-escalation for another a week. Then, 2nd outcome evaluation will be done. Then, after 1 week of no-administration of antibiotics, 3rd outcome evaluation will be undertaken.Basically outcome evaluation is done by symptom of infectious diseases.	—

Countries

Japan

Contacts

Public ContactKatsumi Shigemura

Kobe University Urology

katsumi@med.kobe-u.ac.jp078-382-6155

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026